Drug Trial Radar · NCT03338621
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
455
Actual
Start
Jul 30, 2018
Primary completion
Jul 1, 2021
Study completion Jun 10, 2022
Sponsor
- Lead sponsor
- Global Alliance for TB Drug DevelopmentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients given BPaMZ for 17 Weeks ( or 4 months) vs. Standard HRZE/HR treatment given for 26 weeks (or 6 months) and Drug Resistant TB (DR-TB) patients given BPaMZ for 26 Weeks (or 6 months)
Conditions
- Tuberculosis, Pulmonary
- Tuberculosis, Multidrug-Resistant
- Tuberculosis, MDR
- Tuberculosis
- Drug-Resistant Tuberculosis
Interventions
PretomanidDrug
200 mg tablets
BedaquilineDrug
100 mg tablets
MoxifloxacinDrug
400 mg tablets
PyrazinamideDrug
500 mg tablets
HRZEDrug
isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets
HRDrug
isoniazid 75 mg plus rifampicin 150 mg combination tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Culture Negative Status by 8 WeeksTime frame: Days 0-56 (8 weeks)
Locations
26 sites in 8 countries. Site status is shown where the registry gives one.
Evandro Chagas
Rio de Janeiro, Brazil
FIOCRUZ
Rio de Janeiro, Brazil
National Center for Tuberculosis and Lung Diseases
Tbilisi, K'alak'i T'bilisi, Georgia
Institut Perubatan Respiratori
Kuala Lumpur, Malaysia
Lung Center of Philippines
Manila, Philippines
Tropical Disease Foundation
Manila, Philippines
Moscow City Research and Practice Tuberculosis Treatment Centre
Moscow, Russia
Central TB Research Institute of the Federal Agency of Scientific Organizations
Moscow, Russia
Research Institute of Phthisiopulmonology of I. M. Sechenov First Moscow State Medical University
Moscow, Russia
Research Institute of the Phthisiopulmonology
Saint Petersburg, Russia
Ural Research Institute of Phthisiopulmonology
Yekaterinburg, Russia
Madibeng Centre for Research
Brits, South Africa
TASK
Cape Town, South Africa
University of Cape Town Lung Institute
Cape Town, South Africa
Enhancing Care Foundation
Durban, South Africa
CHRU, King Dinuzulu
Durban, South Africa
CHRU, Helen Joseph Hospital
Johannesburg, South Africa
PHRU, Tshepong Hospital
Klerksdorp, South Africa
CHRU, Empilweni TB Hospital
Port Elizabeth, South Africa
Setshaba Research Centre
Soshanguve, South Africa
THINK
Pietermaritzburg, KwaZulu-Natal, South Africa
Ifakara Health Institute
Bagamoyo, Tanzania
NIMR-Mbeya
Mbeya, Tanzania
Kilimanjaro Clinical Research Institute
Moshi, Tanzania
Mwanza Intervention Trials Unit
Mwanza, Tanzania, Tanzania
Case Western Reserve University
Kampala, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.